Oncology and BRAF-altered cancers
Fore Biotherapeutics Inc. focuses on clinical research in solid tumors</span and primary central nervous system tumors with BRAF alterations, including BRAF fusions and BRAF V600E mutations.
- Locally advanced solid tumors
- Metastatic cancer
- Rare solid tumors
- Recurrent primary CNS tumors
The sponsor’s clinical activity is centered on targeted treatment strategies for cancers driven by specific BRAF pathway changes.
Neurologic cancer research
Its trial portfolio includes tumors arising in the central nervous system, with attention to recurrent or progressive CNS disease linked to actionable BRAF alterations.
- Primary CNS tumors
- Progressive brain tumors
- Genomically defined CNS malignancies
Research in this area reflects interest in difficult-to-treat neurologic malignancies where molecular profiling guides therapeutic selection.
Precision oncology
Fore Biotherapeutics Inc. supports studies built around molecularly defined cancer subsets, with emphasis on tumors characterized by BRAF class 1 and class 2 alterations.
- Targeted therapy development
- Genomic alteration-driven cancer care
- Actionable oncogenic signaling pathways
The sponsor’s research interests are concentrated on matching treatment approaches to the underlying tumor biology.
